Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $157.07, for a total transaction of $471,210.00. Following the completion of the transaction, the insider now owns 133,205 shares in the company, valued at approximately $20,922,509.35. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Thursday, May 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $150.12, for a total value of $450,360.00.
• On Monday, April 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The stock was sold at an average price of $152.18, for a total transaction of $335,709.08.
• On Tuesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $140.48, for a total transaction of $421,440.00.
• On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04.

Natera Stock Up 4.4%

Shares of NTRA traded up $7.07 during mid-day trading on Wednesday, reaching $167.22. 1,334,039 shares of the stock traded hands, compared to its average volume of 1,406,394. The firm has a market cap of $22.83 billion, a price-to-earnings ratio of -95.01 and a beta of 1.79. The stock has a fifty day simple moving average of $150.83 and a 200 day simple moving average of $158.58. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. During the same quarter in the previous year, the firm posted ($0.56) EPS. The firm's quarterly revenue was up 36.5% on a year-over-year basis. Sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. UBS Group increased their target price on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Robert W. Baird raised their price objective on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Finally, Barclays raised their price target on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently modified their holdings of NTRA. LRI Investments LLC purchased a new stake in shares of Natera during the fourth quarter worth about $29,000. Bank of Jackson Hole Trust purchased a new stake in Natera during the 1st quarter worth approximately $29,000. Blue Trust Inc. increased its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Rakuten Securities Inc. increased its holdings in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares during the last quarter. Finally, ORG Partners LLC bought a new stake in shares of Natera in the first quarter worth $32,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.